01 September 1997
Effect of ornithine-aspartate infusion on elevated serum ammonia concentration in cirrhotic patients - results of a randomized, placebo-controlled double-blind multicentre trialJanos Feher, Istvan Lang, Arpad Gogl, Laszlo Varga, Laszlo Varga, Gabor Tompos, Laszlo Pronai
Med Sci Monit 1997; 3(5): CR669-673 :: ID: 501567
Eighty patients were included in a randomized, double-blind, placebo-controlled multicentre trial to determine the effect of L-ornithine-L-aspartate (Hepa-Merz¨) infusion on serum ammonia level in patients with liver cirrhosis accompanied by hyperammonaemia.Fourty patients received ornithine-aspartate (20 g in 250 ml 0,9% NaCl infusion solution administered intravenously during four hours) and 40 patients received placebo (250 ml 5% fructose solution). The follow-up time was seven days. Patients had alcoholic liver cirrhosis with hyperammonaemia (venous ammonia > 50 µmol/l). Patients treated with other hepatotherapeutic agents and those having alcohol withdrawal syndrome, consumption of alcohol during the study, gastrointestinal bleeding, pregnancy, severe concomitant diseases or fructose intolerance were excluded from the trial. Effect of treatment was evaluated by the clinical course and laboratory parameters of patients (venous ammonia level, g-GT, AST, ALT, AP, glucose, bilirubin, ChE, BUN, creatinine, albumin, prothrombin and hematological parameters) measured at 1, 3, 5 and 7 days of treatment.The seven-day ornithine-aspartate infusion therapy resulted in a significant decrease (p<0,05) of fasting ammonia concentration (-32%) when compared with that in the placebo group (-15%). There was no significant improvement in the routine laboratory parameters measured. Good tolerability and low rate of side effects were reported by the patients. In view of its demonstrated effect, ornithine-aspartate infusion can be considered as an effective therapy to decrease elevated serum ammonia level in cirrhotic patients.
Keywords: Liver Cirrhosis, ornithine-aspartate, hyperammonaemia
15 August 2022 : EditorialEditorial: The Metabolic (Dysfunction) Associated Fatty Liver Disease (MAFLD)-Non-Alcoholic Fatty Liver Disease (NAFLD) Debate: A Forced Consensus and The Risk of a World Divide
Med Sci Monit 2022; 28:e938080
12 Aug 2022 : Clinical ResearchRisk Factors and Pathogen Spectrum in Continuous Ambulatory Peritoneal Dialysis-Associated Peritonitis: A S...
Med Sci Monit In Press; DOI: 10.12659/MSM.937112
11 Aug 2022 : Meta-AnalysisOptimal Surgical Treatment Method for Anterior Cruciate Ligament Rupture: Results from a Network Meta-Analysis
Med Sci Monit In Press; DOI: 10.12659/MSM.937118
10 Aug 2022 : Review articleProgrammed Cell Death in Diabetic Nephropathy: A Review of Apoptosis, Autophagy, and Necroptosis
Med Sci Monit In Press; DOI: 10.12659/MSM.937766
Most Viewed Current Articles
30 Dec 2021 : Clinical ResearchRetrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...
Med Sci Monit 2021; 27:e935379
13 Nov 2021 : Clinical ResearchAcceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...
Med Sci Monit 2021; 27:e932788
08 Mar 2022 : Review articleA Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...
Med Sci Monit 2022; 28:e936292